Aardvark Therapeutics, Inc.: CITADEL ADVISORS LLC amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Citadel Advisors LLC amended its Schedule 13G filing with the SEC covering its stake in Aardvark Therapeutics, Inc., under accession number 0001104659-26-128212. The amendment updates the hedge fund's previously reported beneficial ownership position in the clinical-stage biotech, though the filing notice did not disclose the revised share count or percentage. Schedule 13G amendments are typically triggered when passive investors cross or adjust threshold ownership levels, making the disclosure a signal of Citadel's current exposure to the company. Investors will watch for the full filing details to see whether Citadel increased, trimmed or maintained its position, and for any subsequent 13F or 13G updates that clarify the size of the stake.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Citadel Advisors LLC, Aardvark Therapeutics, Inc.